Metformin sensitizes hypoxia-induced gefitinib treatment resistance of HNSCC via cell cycle regulation and EMT reversal

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• MillerKDSiegelRLLinCCCancer treatment and survivorship statistics, 2016CA Cancer J Clin201666427128927253694
   PubMed Web of Science ®Google Scholar
• MarurSForastiereAAHead and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and TreatmentMayo Clin Proc201691338639626944243
   PubMed Web of Science ®Google Scholar
• MetroGEGFR targeted therapy for lung cancer: are we almost there?Transl Lung Cancer Res20187Suppl 2S142S14529782570
   PubMedGoogle Scholar
• BhattiMIppolitoTMavisCPre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphomaOncotarget2018931218202183029774105
   PubMedGoogle Scholar
• YangJYanJLiuBTargeting VEGF/VEGFR to Modulate Antitumor ImmunityFront Immunol2018997829774034
   PubMed Web of Science ®Google Scholar
• ToschiLRossiSFinocchiaroGSantoroANon-small cell lung cancer treatment (r)evolution: ten years of advances and more to comeEcancermedicalscience20171178729225694
   PubMedGoogle Scholar
• KalyankrishnaSGrandisJREpidermal growth factor receptor biology in head and neck cancerJ Clin Oncol200624172666267216763281
   PubMed Web of Science ®Google Scholar
• SoulieresDSenzerNNVokesEEHidalgoMAgarwalaSSSiuLLMulticenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neckJ Clin Oncol2004221778514701768
   PubMed Web of Science ®Google Scholar
• MagnesTEgleAGreilRMelchardtTUpdate on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017Memo201710422022329250200
   PubMedGoogle Scholar
• CohenEERosenFStadlerWMPhase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neckJ Clin Oncol200321101980198712743152
   PubMed Web of Science ®Google Scholar
• MasekiSIjichiKTanakaHAcquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathwayBr J Cancer201210661196120422315058
   PubMed Web of Science ®Google Scholar
• JamesonMJBecklerADTaniguchiLEActivation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cellsMol Cancer Ther201110112124213421878657
   PubMed Web of Science ®Google Scholar
• JiaYYunCHParkEOvercoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsNature2016534760512913227251290
   PubMed Web of Science ®Google Scholar
• OcañaMCMartínez-PovedaBQuesadaARMedinaMÁMetabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic targetMed Res Rev Epub2018522
   PubMed Web of Science ®Google Scholar
• MaSPradeepSHuWZhangDColemanRSoodAThe role of tumor microenvironment in resistance to anti-angiogenic therapyF1000Res2018732629560266
   PubMedGoogle Scholar
• MurakamiATakahashiFNurwidyaFHypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptorPLoS One201491e8645924489728
   PubMed Web of Science ®Google Scholar
• MinakataKTakahashiFNaraTHypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptorsCancer Sci2012103111946195422863020
   PubMed Web of Science ®Google Scholar
• HanSXuWWangZCrosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironmentOncotarget2016725377733778927191981
   PubMedGoogle Scholar
• Wahdan-AlaswadRSEdgertonSMSalemHSThorADMetformin Targets Glucose Metabolism in Triple Negative Breast CancerJ Oncol Transl Res201841pii:129
   Google Scholar
• TsengCHMetformin and risk of developing nasopharyngeal cancer in patients with type 2 diabetes mellitusMetabolism20188522322629729227
   PubMed Web of Science ®Google Scholar
• WooSHYangLPChuangHCDown-regulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy-induced senescenceHead Neck201638Suppl 1E934E94025994759
   PubMedGoogle Scholar
• QiXXuWXieJMetformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-κB/HIF-1α signal axisSci Rep201663578827762347
   PubMed Web of Science ®Google Scholar
• ShienKToyookaSYamamotoHAcquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cellsCancer Res201373103051306123542356
   PubMed Web of Science ®Google Scholar
• KohnohTHashimotoNAndoAHypoxia-induced modulation of PTEN activity and EMT phenotypes in lung cancersCancer Cell Int2016163327095949
   PubMed Web of Science ®Google Scholar
• FryDWHarveyPJKellerPRSpecific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenograftsMol Cancer Ther20043111427143815542782
   PubMed Web of Science ®Google Scholar
• RekaAKKuickRKurapatiHStandifordTJOmennGSKeshamouniVGIdentifying inhibitors of epithelial–mesenchymal transition by connectivity map-based systems approachJ Thorac Oncol20116111784179221964532
   PubMed Web of Science ®Google Scholar
• CamachoLDasguptaAJiralerspongSMetformin in breast cancer - an evolving mysteryBreast Cancer Res2015178826111812
   PubMed Web of Science ®Google Scholar
• YouACaoMGuoZMetformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse modelsJ Hematol Oncol201692026957312
   PubMed Web of Science ®Google Scholar
• El-ArabeyAANew insight for metformin against bladder cancerGenes Environ2017391328373897
   PubMed Web of Science ®Google Scholar
• JanmaatMLKruytFARodriguezJAGiacconeGResponse to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathwaysClin Cancer Res2003962316232612796401
   PubMed Web of Science ®Google Scholar
• Al-WahabZMertITebbeCMetformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restrictionOncotarget2015613109081092325895126
   PubMedGoogle Scholar
• LiLHanRXiaoHMetformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversalClin Cancer Res201420102714272624644001
   PubMed Web of Science ®Google Scholar
• OnnATsuboiMThatcherNTreatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinibBr J Cancer200491Suppl 2S11S1715340373
   PubMedGoogle Scholar
• TetsuOHangauerMJPhuchareonJEiseleDWMccormickFDrug Resistance to EGFR Inhibitors in Lung CancerChemotherapy201661522323526910730
   PubMed Web of Science ®Google Scholar
• StegemanHKaandersJHWheelerDLActivation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neckBMC Cancer20121246323046567
   PubMed Web of Science ®Google Scholar
• VigneswaranNWuJSongAAnnapragadaAZachariasWHypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC)Exp Mol Pathol201190221522521236253
   PubMed Web of Science ®Google Scholar
• LöckSPerrinRSeidlitzAResidual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imagingRadiother Oncol2017124353354028843726
   PubMed Web of Science ®Google Scholar
• AnSMLeiHMDingXPInterleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cellsOncol Lett20171433445345428927099
   PubMed Web of Science ®Google Scholar
• XuSYangZJinPMetformin suppresses tumor progression by inactivating stromal fibroblasts in ovarian cancerMol Cancer Ther20181761291130229545331
   PubMed Web of Science ®Google Scholar
• SuiXXuYWangXMetformin: A Novel but Controversial Drug in Cancer Prevention and TreatmentMol Pharm201512113783379126430787
   PubMed Web of Science ®Google Scholar
• SivalingamVMcveyRGilmourKA presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancerLancet2015385Suppl 1S9026312913
   PubMedGoogle Scholar
• IliopoulosDHirschHAStruhlKMetformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell typesCancer Res20117193196320121415163
   PubMed Web of Science ®Google Scholar
• Reagan-ShawSNihalMAhmadNDose translation from animal to human studies revisitedFASEB J200822365966117942826
   PubMed Web of Science ®Google Scholar
• MorgilloFFasanoMdella CorteCMResults of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancerESMO Open201722e00013228761738
   PubMed Web of Science ®Google Scholar